JNCE logo

Jounce Therapeutics (JNCE) Cash From Investing

Annual CFI

$83.48 M
+$143.99 M+237.95%

December 31, 2022

Summary

Performance

1-Year Change

+237.95%

3-Year Change

+166.01%

5-Year Change

+319.56%

15-Year Change

+319.56%

JNCE Cash From Investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$86.41 M
JNCE annual cash flow from investing activities is currently -3.40% below its historical high of $86.41 million

3-Year Low

-$60.51 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
JNCE previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

N/A
JNCE next annual earnings announcement has not yet been scheduled

OtherJNCEcash flowmetrics:

Annual CFF

$442.00 K
JNCE annual cash flow from financing activities is $442.00 thousand

Annual CFO

-$28.88 M
JNCE annual cash flow from operations is -$28.88 million

Annual FCF

-$29.80 M
JNCE annual free cash flow is -$29.80 million

Annual CAPEX

$919.00 K
JNCE annual capital expenditures is $919.00 thousand

Quarterly CFI

$14.23 M
-$16.68 M-53.97%

December 31, 2022

Summary

Performance

3-Month Change

-53.97%

1-Year Change

+165.61%

3-Year Change

+736.39%

5-Year Change

-23.86%

JNCE Quarterly CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$119.58 M
JNCE quarterly cash flow from investing activities is currently -88.10% below its historical high of $119.58 million

3-Year Low

-$21.68 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2022
JNCE previous earnings announcement was published on Dec 31, 2022

Next Quarterly Earnings Report Date

N/A
JNCE next earnings announcement has not yet been scheduled

OtherJNCEcash flowmetrics:

Quarterly CFF

$0.00
JNCE quarterly cash flow from financing activities is $0.00

Quarterly CFO

$59.23 M
JNCE quarterly cash flow from operations is $59.23 million

Quarterly FCF

$59.01 M
JNCE quarterly free cash flow is $59.01 million

Quarterly CAPEX

$223.00 K
JNCE quarterly capital expenditures is $223.00 thousand

TTM CFI

$83.48 M
+$35.91 M+75.50%

December 31, 2022

Summary

Performance

3-Month Change

+75.5%

1-Year Change

+237.95%

3-Year Change

+166.01%

5-Year Change

+166.01%

JNCE TTM CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$154.41 M
JNCE TTM cash flow from investing activities is currently -45.94% below its historical high of $154.41 million

3-Year Low

-$60.51 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2022
JNCE previous earnings announcement was published on Dec 31, 2022

Next Quarterly Earnings Report Date

N/A
JNCE next earnings announcement has not yet been scheduled

OtherJNCEcash flowmetrics:

TTM CFF

$442.00 K
JNCE TTM cash flow from financing activities is $442.00 thousand

TTM CFO

-$28.88 M
JNCE TTM cash flow from operations is -$28.88 million

TTM FCF

-$29.80 M
JNCE TTM free cash flow is -$29.80 million

TTM CAPEX

$919.00 K
JNCE TTM capital expenditures is $919.00 thousand

Cash From Investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

JNCE Cash From Investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+237.9%+165.6%+237.9%
3 y3 years+166.0%+736.4%+166.0%
5 y5 years+319.6%-23.9%+166.0%

JNCE Cash From Investing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high-172.5%-65.0%-252.4%at high-172.5%
5 y5-yearat high-172.5%-67.5%-314.5%at high-179.7%
alltimeall time-3.4%-358.2%-88.1%-1385.5%-45.9%-445.1%

Jounce Therapeutics Cash From Investing History

DateAnnualQuarterlyTTM
Dec 2022
$83.48 M(-237.9%)
$14.23 M(-54.0%)
$83.48 M(+75.5%)
Sep 2022
-
$30.91 M(-24.1%)
$47.57 M(+164.7%)
Jun 2022
-
$40.70 M(-1824.6%)
$17.97 M(-133.7%)
Mar 2022
-
-$2.36 M(-89.1%)
-$53.25 M(-12.0%)
Dec 2021
-$60.51 M(-218.0%)
-$21.68 M(-1754.0%)
-$60.51 M(-9.1%)
Sep 2021
-
$1.31 M(-104.3%)
-$66.56 M(+24.6%)
Jun 2021
-
-$30.52 M(+217.1%)
-$53.43 M(+2482.3%)
Mar 2021
-
-$9.62 M(-65.3%)
-$2.07 M(-104.0%)
Dec 2020
$51.30 M(+63.5%)
-$27.73 M(-292.0%)
$51.30 M(-36.5%)
Sep 2020
-
$14.44 M(-30.7%)
$80.73 M(+31.3%)
Jun 2020
-
$20.84 M(-52.4%)
$61.50 M(+2.9%)
Mar 2020
-
$43.74 M(+2471.7%)
$59.75 M(+90.4%)
Dec 2019
$31.38 M
$1.70 M(-135.5%)
$31.38 M(-27.8%)
Sep 2019
-
-$4.79 M(-125.1%)
$43.49 M(-37.7%)
Jun 2019
-
$19.09 M(+24.1%)
$69.82 M(-492.5%)
DateAnnualQuarterlyTTM
Mar 2019
-
$15.38 M(+11.3%)
-$17.79 M(-120.6%)
Dec 2018
$86.41 M(-327.3%)
$13.81 M(-35.9%)
$86.41 M(-5.3%)
Sep 2018
-
$21.54 M(-131.4%)
$91.28 M(+14.7%)
Jun 2018
-
-$68.52 M(-157.3%)
$79.56 M(-48.5%)
Mar 2018
-
$119.58 M(+540.0%)
$154.41 M(-506.1%)
Dec 2017
-$38.02 M(-82.4%)
$18.68 M(+90.4%)
-$38.02 M(-57.1%)
Sep 2017
-
$9.81 M(+54.9%)
-$88.69 M(-68.5%)
Jun 2017
-
$6.33 M(-108.7%)
-$281.39 M(-2.3%)
Mar 2017
-
-$72.85 M(+127.8%)
-$288.11 M(+33.7%)
Dec 2016
-$215.51 M(>+9900.0%)
-$31.98 M(-82.5%)
-$215.51 M(+17.4%)
Sep 2016
-
-$182.89 M(>+9900.0%)
-$183.53 M(>+9900.0%)
Jun 2016
-
-$384.00 K(+53.6%)
-$634.00 K(+153.6%)
Mar 2016
-
-$250.00 K
-$250.00 K
Dec 2015
-$2.14 M(+202.1%)
-
-
Dec 2014
-$709.00 K
-
-

FAQ

  • What is Jounce Therapeutics annual cash flow from investing activities?
  • What is the all time high annual CFI for Jounce Therapeutics?
  • What is Jounce Therapeutics annual CFI year-on-year change?
  • What is Jounce Therapeutics quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for Jounce Therapeutics?
  • What is Jounce Therapeutics quarterly CFI year-on-year change?
  • What is Jounce Therapeutics TTM cash flow from investing activities?
  • What is the all time high TTM CFI for Jounce Therapeutics?
  • What is Jounce Therapeutics TTM CFI year-on-year change?

What is Jounce Therapeutics annual cash flow from investing activities?

The current annual CFI of JNCE is $83.48 M

What is the all time high annual CFI for Jounce Therapeutics?

Jounce Therapeutics all-time high annual cash flow from investing activities is $86.41 M

What is Jounce Therapeutics annual CFI year-on-year change?

Over the past year, JNCE annual cash flow from investing activities has changed by +$143.99 M (+237.95%)

What is Jounce Therapeutics quarterly cash flow from investing activities?

The current quarterly CFI of JNCE is $14.23 M

What is the all time high quarterly CFI for Jounce Therapeutics?

Jounce Therapeutics all-time high quarterly cash flow from investing activities is $119.58 M

What is Jounce Therapeutics quarterly CFI year-on-year change?

Over the past year, JNCE quarterly cash flow from investing activities has changed by +$35.91 M (+165.61%)

What is Jounce Therapeutics TTM cash flow from investing activities?

The current TTM CFI of JNCE is $83.48 M

What is the all time high TTM CFI for Jounce Therapeutics?

Jounce Therapeutics all-time high TTM cash flow from investing activities is $154.41 M

What is Jounce Therapeutics TTM CFI year-on-year change?

Over the past year, JNCE TTM cash flow from investing activities has changed by +$143.99 M (+237.95%)